Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 293

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 293
---
 be reasonably expected to trade below the current redemption price of the Public Shares. If this scenario were to materialize, the Public Shareholders would have been better off redeeming rather than holding Company Shares post-business combination. |
| OmnigenicsAI and affiliates         |     | After the consummation of the Business Combination, the Company Shares are expected to be listed on Nasdaq. As a U.S. public company, OmnigenicsAI and therefore, OmnigenicsAI’s legacy stockholders, will enjoy enhanced visibility in the capital markets, which could help amplify the brand awareness of OmnigenicsAI and increase the revenue of OmnigenicsAI.        |     | OmnigenicsAI has and continues to incur significant fees and expenses associated with completing the Business Combination and OmnigenicsAI’s management has invested substantial time and effort to complete the Business Combination as well as the risks that the benefits sought to be achieved by the Business Combination might not be achieved fully or may not                                                                                                                    |

136

| Stakeholder |     | Benefits                                                                                                                                                                                                                                                                                                                                                                             |     | Detriments                                                                                                                                                                                         |
|             |     | In addition, OmnigenicsAI will be able to raise funds through the U.S. public capital markets, providing it with access to capital to execute its expansion and growth strategies.                                                                                                                                                                                                   
 Further, OmnigenicsAI’s legacy shareholders had (directly or indirectly) acquired their respective shares of OmnigenicsAI at a price lower than $10.00 per Company Share. To the extent that the Company Shares will trade above their per share acquisition price, legacy OmnigenicsAI stockholders will receive a positive return on their respective investments in OmnigenicsAI. 
 See also “Questions and Answers About the Business Combination and the Special Meeting — What interests do our Initial Shareholders, current officers, directors and advisors, and the Company’s current shareholders have in the Business Combination?” for a description of other benefits of the Business Combination to OmnigenicsAI and its affiliates.                         |     | be achieved within the expected timeframe and that completion of the Business Combination is conditioned on satisfaction of certain closing conditions that are not within OmnigenicsAI’s control. |

Interests of APx’s Directors and Officers in the Business Combination See “ Questions and Answers About the Business Combination and the Special Meeting — What interests do our Initial Shareholders, current officers, directors and advisors, and the Company’s current shareholders have in the Business Combination?” Regulatory Approvals Required for the Business Combination Non -U.S. regulatory bodies and U